291
Participants
Start Date
March 1, 2014
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
AG-120
AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
ACTIVE_NOT_RECRUITING
Memorial Sloan Kettering Cancer Center, New York
TERMINATED
Cornell Cancer Center, New York
ACTIVE_NOT_RECRUITING
John Hopkins Cancer Center, Baltimore
TERMINATED
Duke Cancer Center, Durham
RECRUITING
Medical University of South Carolina, Charleston
ACTIVE_NOT_RECRUITING
Emory University, Atlanta
TERMINATED
Mayo Clinic-Jacksonville, Jacksonville
TERMINATED
University of Miami, Miami
RECRUITING
Hopital Haut-Leveque, Pessac
ACTIVE_NOT_RECRUITING
Moffit Cancer Center, Tampa
ACTIVE_NOT_RECRUITING
University of Alabama at Birmingham, Birmingham
TERMINATED
Sarah Cannon Research Institute, Nashville
TERMINATED
Ohio State University, Columbus
WITHDRAWN
Cleveland Clinic, Cleveland
TERMINATED
Karmanos Cancer Center, Detroit
TERMINATED
Northwestern University Medical Hospital, Chicago
TERMINATED
Washington University, St Louis
RECRUITING
Central Lyon Sud, Pierre-Bénite
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
MD Anderson Cancer Center, Houston
TERMINATED
University of Colorado Denver, Aurora
TERMINATED
Mayo Clinic-AZ, Phoenix
TERMINATED
University of California-Los Angeles, Los Angeles
ACTIVE_NOT_RECRUITING
City of Hope, Duarte
TERMINATED
University of California-San Francisco, San Francisco
RECRUITING
Institute Gustave Roussly (IGR), Villejuif
TERMINATED
Oregon Health and Science University, Portland
TERMINATED
Massachusetts General Hospital, Boston
TERMINATED
Dana Farber Cancer Institute, Boston
TERMINATED
Hopital La Timone, Marseille
Institut de Recherches Internationales Servier
OTHER